Clinical validation of sublingual formulations of Immunoxel (Dzherelo) as an adjuvant immunotherapy in treatment of TB patients

Immunotherapy

Volumn 4, Issue 3, 2012, Pages 273-282

  Efremenko, Yuri V ^a   Arjanova, Olga V ^a   Prihoda, Natalia D ^a   Yurchenko, Larisa V ^a   Sokolenko, Nina I ^a   Mospan, Igor V ^b   Pylypchuk, Volodymyr S ^b   Rowe, John ^c   Jirathitikal, Vichai ^d   Bourinbaiar, Aldar S ^e   Kutsyna, Galyna A ^f  

^a Lisichansk Tuberculosis Dispensary   (Ukraine)

^b Ekomed LLC   (Ukraine)

^c Island Abbey Foods Ltd   (Canada)

^d Bangpakong Industrial Park   (Thailand)

^e Immunitor USA Inc   (United States)

^f Lugansk State Medical University   (Ukraine)

Author keywords

biomarker; immunomodulator; immunotherapy; inflammation; mycobacterium; phytomedicine

Indexed keywords

DZHERELO; ETHAMBUTOL; GELATIN; HEMOGLOBIN; IMMUNOXEL; ISONIAZID; PLACEBO; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; SUGAR; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; ARTICLE; BODY WEIGHT; CHEMOTHERAPY; CONTROLLED STUDY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENDER; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; LEUKOCYTE COUNT; LOZENGE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; PILL; PRIORITY JOURNAL; SPUTUM ANALYSIS; SUBLINGUAL IMMUNOTHERAPY; TUBERCULOSIS; VALIDATION STUDY;

ADMINISTRATION, SUBLINGUAL; ADULT; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; PHYTOTHERAPY; PLANT PREPARATIONS; TIME FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT; UKRAINE;

EID: 84858317995     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.11.176     Document Type: Article

References (34)

1. Nuermberger EL, Spigelman MK, Yew WW. Current development and future prospects in chemotherapy of tuberculosis. Respirology 15, 764-778 (2010).
2. Casenghi M, Cole ST, Nathan CF. New approaches to filling the gap in tuberculosis drug discovery. PLoS Med. 4, e293 (2007).
3. Churchyard GJ, Kaplan G, Fallows D, Wallis RS, Onyebujoh P, Rook GA. Advances in immunotherapy for tuberculosis treatment. Clin. Chest Med. 30, 769-782 (2009).
4. Dheda K, Schwander SK, Zhu B, van Zyl-Smit RN, Zhang Y. The immunology of tuberculosis: from bench to bedside. Respirology 15, 433-450 (2010).
5. Grange JM, Brunet LR, Rieder HL. Immune protection against tuberculosis - when is immunotherapy preferable to vaccination? Tuberculosis 91, 179-185 (2011).
6. Silin DS, Lyubomska OV, Ershov FI, Frolov VM, Kutsyna GA. Immunomodulators with interferon inducing properties. Curr. Pharm. Des. 15, 1238-1247 (2009).
7. Patwardhan B, Gautam M. Botanical immunodrugs: scope and opportunities. Drug Discov. Today 10, 495-502 (2005). (Pubitemid 40487492)
8. Denzler KL, Waters R, Jacobs BL, Rochon Y, Langland JO. Regulation of inflammatory gene expression in PBMCs by immunostimulatory botanicals. PLoS ONE 5, e12561 (2010).
9. Bladt S, Wagner H. From the Zulu medicine to the European phytomedicine Umckaloabo. Phytomedicine 14(Suppl. 6), 2-4 (2007). (Pubitemid 46209776)
10. Sherry E, Warnke PH. Successful use of an inhalational phytochemical to treat pulmonary tuberculosis: a case report. Phytomedicine 11, 95-97 (2004). (Pubitemid 38314047)
11. Galitskií LA, Barnaulov OD, Zaretskií BV, et al. Effect of phytotherapy on the prevention and elimination of hepatotoxic responses in patients with pulmonary tuberculosis, carriers of hepatitis B virus markers. Probl. Tuberk. 4, 35-38 (1997).
12. Tan BKH, Vanitha J. Immunomodulatory and antimicrobial effects of some traditional Chinese medicinal herbs: a review. Curr. Med. Chem. 11, 1423-1430 (2004). (Pubitemid 38735787)
13. Gautam R, Saklani A, Jachak SM. Indian medicinal plants as a source of antimycobacterial agents. J. Ethnopharmacol. 110, 200-234 (2007).
14. Chechitiany R, Pylypchuk V, Arjanova O, et al. Comparative effect of an immunomodulator Immunoxel (Dzherelo) when used alone or in combination with antiretroviral therapy in drug-naive HIV infected individuals. Int. J. Biotechnol. 9, 267-276 (2007).
15. Prihoda ND, Arjanova OV, Yurchenko LV, et al. Open label trial of adjuvant immunotherapy with Dzherelo, svitanok and lizorm, in MDR-TB, XDR-TB and TB/HIV co-infected patients receiving anti-tuberculosis therapy under DOT. J. Med. Plants Res. 1, 117-122 (2007).
16. 4+ T-lymphocyte counts and viral load in HIV infected patients receiving anti-retroviral therapy. Res. J. Pharmacol. 2, 8-12 (2008). (Pubitemid 351780993)
17. Nikolaeva LG, Maystat TV, Pylypchuk VS, Volyanskii YL, Masyuk LA, Kutsyna GA. Effect of oral immunomodulator Dzherelo (Immunoxel) in TB/HIV co-infected patients receiving anti-tuberculosis therapy under DOTS. Int. Immunopharmacol. 8, 845-851 (2008).
18. 4+ T-cells and HIV RNA resulting from combination of anti-TB therapy with Dzherelo in TB/HIV dually infected patients. Drug Des. Dev. Ther. 2, 87-93 (2008).
19. Prihoda ND, Arjanova OV, Yurchenko LV, et al. Adjuvant immunotherapy of tuberculosis in drug-resistant TB and TB/HIV co-infected patients. Int. J. Biomed. Pharm. Sci. 2, 59-64 (2008).
20. Nikolaeva LG, Maystat TV, Pylypchuk VS, Volyanskii YuL, Frolov VM, Kutsyna GA. Cytokine profiles of patients with pulmonary tuberculosis resulting from adjunct immunotherapy with herbal phytoconcentrates Dzherelo and Anemin. Cytokine 44, 392-396 (2008).
21. Zaitzeva SI, Matveeva SL, Gerasimova TG, et al. Efficacy and safety of phytoconcentrate Dzherelo (Immunoxel) in treatment of patients with multi-drug resistant TB (MDR-TB) in comparison to standard chemotherapy. Res. J. Med. Sci. 3, 36-41 (2009).
22. Nikolaeva LG, Maystat TV, Pylypchuk VS, Volyanskii YL, Frolov VM, Kutsyna GA. Effect of immunomodulating adjuvant Dzherelo (Immunoxel) in HIV infected patients receiving standard antiretroviral therapy. Open J. Virol. 3, 31-36 (2009).
23. Zaitzeva SI, Matveeva SL, Gerasimova TG, et al. Treatment of cavitary and infiltrating pulmonary TB with or without immunomodulator Dzherelo. Clin. Microbiol. Infect. 15, 1154-1162 (2009).
24. Arjanova OV, Prihoda ND, Sokolenko NI, et al. Enhancement of the efficacy of tuberculosis drugs with oral immunomodulator Dzherelo (Immunoxel) in HIV-infected patients with active pulmonary TB. Immunotherapy 1, 549-556 (2009).
25. Prihoda ND, Arjanova OV, Yurchenko LV, et al. Adjuvant immunotherapy of extensively drug-resistant tuberculosis (XDR-TB) in Ukraine. Curr. Res. TB 1, 9-14 (2009).
26. Arjanova OV, Prihoda ND, Sokolenko NI, et al. Impact of adjunct immunotherapy with multi-herbal supplement Dzherelo (Immunoxel) on treatment outcomes in end-stage TB/HIV patients. J. Antivir. Antiretrovir. 1, 86-88 (2009).
27. Pothmann FJ. Effect of honey upon the growth of tubercle bacilli. Z. Hyg. Infektionskr. 130, 468-484 (1950).
28. Ulker N. Antibacterial action of honey toward different types of Mycobacterium. Turk. Tip. Cemiyeti. Mecmuasi. 33, 282-287 (1967).
29. Iareshko AG, Golenitskii AI, Iareshko VA, Zakharchenko AA. Effect of flower honey and its products on the M. tuberculosis. Probl. Tuberk. 3, 83-84 (1978).
30. Asadi-Pooya AA, Pnjehshahin MR, Beheshti S. The antimycobacterial effect of honey: an in vitro study. Riv. Biol. 96, 491-495 (2003). (Pubitemid 38318768)
31. Pereira PCM, Barraviera B, Burini RC, Soares AMVC, Bertani MA. Use of honey as nutritional and therapeutic supplement in the treatment of infectious diseases. J. Venom. Anim. Toxins 1, 2 (1995).
32. Sharma M, Khayyam KU, Kumar V, Imam F, Pillai KK, Behera D. Influence of honey on adverse reactions due to anti-tuberculosis drugs in pulmonary tuberculosis patients. Cont. J. Pharm. Tox. Res. 2, 6-11 (2008).
33. Newton SM, Lau C, Wright CW. A review of antimycobacterial natural products. Phytother. Res. 14, 303-322 (2000). (Pubitemid 30655514)
34. Adjunct Immunotherapy With Immunoxel in Patients With TB and TB/HIV. http://clinicaltrials.gov/ct2/show/ NCT01061593